Pancreatic cancer, known for its aggressiveness, has seen limited improvements in survival rates over the past decade.
A Mayo Clinic study is providing new insights into how treatment sequence can affect survival in patients with early-stage pancreatic cancer, suggesting that many patients may benefit from receiving ...
CHICAGO — For patients with pancreatic resectable stage I-Ill pancreatic ductal adenocarcinoma (PDAC), neoadjuvant chemotherapy can help improve overall survival compared with upfront surgery. But ...
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven ...
GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...
New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS ...
Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.
Venous thromboembolism is associated with worse survival in patients with pancreatic ductal adenocarcinoma receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results